(19)
(11) EP 2 311 984 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
28.12.2011 Bulletin 2011/52

(43) Date of publication:
20.04.2011 Bulletin 2011/16

(21) Application number: 10177084.0

(22) Date of filing: 02.12.2005
(27) Previously filed application:
 02.12.2005 EP 09010002
(51) International Patent Classification (IPC): 
C12Q 1/68(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30) Priority: 02.12.2004 US 632426 P
02.12.2004 US 633250 P
14.03.2005 US 662220 P
03.10.2005 US 723125 P
03.10.2005 US 723054 P
30.11.2005 US 740736 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
09010002.5 / 2213749
05853011.4 / 1831399

(71) Applicant: Epigenomics AG
10178 Berlin (DE)

(72) Inventors:
  • Cottrell, Susan
    Seattle, WA 98115 (US)
  • Model, Fabian
    12683 Berlin (DE)
  • Haefliger, Carolina
    4052 Basel (CH)
  • Weiss, Gunter
    10437 Berlin (DE)
  • Distler, Jürgen
    12163 Berlin (DE)
  • Sledziewski, Andrew Z.
    Shoreline, WA 98177 (US)
  • Song, Xiaoling
    Woodinville, WA 98072 (US)
  • Skillman, Thomas L.
    Kennydale, WA 98056 (US)
  • Thomas, Jeffrey G.
    San Francisco, CA 94158 (US)

(74) Representative: Zwicker, Jörk et al
Dr. Volker Vossius Patent- und Rechtsanwaltskanzlei Geibelstrasse 6
81679 München
81679 München (DE)

 
Remarks:
The complete document including Reference Tables and the Sequence Listing can be downloaded from the EPO website
Remarks:
This application was filed on 16-09-2010 as a divisional application to the application mentioned under INID code 62.
 


(54) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders


(57) Particular aspects provide novel methods and compositions (e.g., nucleic acids, kits, etc.) having substantial utility for providing a prognosis of prostate cell proliferative disorders. In particular aspects, this is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.